Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Op-T LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, CHESTNUT, BARRY A, who is the busiest examiner with 1 pending action. The matter is assigned to 1 distinct art unit. The current prosecution activity is concentrated under a single examiner, representing the only active point of contact for the portfolio's pending matters.
For the practitioner, this centralization means that the success of the current prosecution cycle depends entirely on the interaction with CHESTNUT, BARRY A. There are no other pending matters to provide a broader context of how different examiners in the same field might view the company's technology. The fact that the 1 pending action is also the only action for the busiest examiner suggests that the examiner's attention is not divided across multiple cases for this specific applicant. This singular focus can be advantageous for building a consistent record, but it also means there is no diversification of risk across different art units or examiners. The practitioner must tailor the strategy specifically to the Biotechnology & Pharmaceuticals standards applied by this single examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18746393 | BIOACTIVE PEPTIDES AND METHODS OF USE THEREOF | CHESTNUT, BARRY A | 1672 | §103DP | Non-Final OA | — | Pending | Jun 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOp-T LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Barry A Chestnut has the most, with 1 of Op-T LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
